# Bromazepam
*Source: https://go.drugbank.com/drugs/DB01558*

## Overview

### Description

This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.

### Background

One of the benzodiazepines that is used in the treatment of anxiety disorders. It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances. It is a intermediate-acting benzodiazepine.

### Indication

For the short-term treatment of insomnia, short-term treatment of anxiety or panic attacks, if a benzodiazepine is required, and the alleviation of the symptoms of alcohol- and opiate-withdrawal.

### Pharmacodynamics

Bromazepam is a lipophilic, long-acting benzodiazepine and with sedative, hypnotic, anxiolytic and skeletal muscle relaxant properties. It does not possess any antidepressant qualities. Bromazepam, like other benzodiazepines, presents a risk of abuse, misuse, and dependence. According to many psychiatric experts, Bromazepam has a greater abuse potential than other benzodiazepines because of fast resorption and rapid onset of action.

### Mechanism of Action

GABA(A) Receptor
Positive allosteric modulator
GABA(A) Receptor Benzodiazepine Binding Site
Ligand

### Absorption

Bioavailability is 84% following oral administration. The time to peak plasma level is 1 - 4 hours. Bromazepam is generally well absorbed after oral administration.

### Metabolism

Hepatically, via oxidative pathways (via an enzyme belonging to the Cytochrome P450 family of enzymes). One of the main metabolites is 3-hydroxybromazepam. It is pharmacologically active and the half life is similar to that of the parent compound.

### Half-life

10-20 hours

### Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

1,2-Benzodiazepine
The risk or severity of CNS depression can be increased when Bromazepam is combined with 1,2-Benzodiazepine.
Abacavir
Abacavir may decrease the excretion rate of Bromazepam which could result in a higher serum level.
Abametapir
The serum concentration of Bromazepam can be increased when it is combined with Abametapir.
Abatacept
The metabolism of Bromazepam can be increased when combined with Abatacept.
Abiraterone
The serum concentration of Bromazepam can be increased when it is combined with Abiraterone.

### Food Interactions

Avoid alcohol. Ingesting alcohol may increase the sedative and CNS depressant effects of bromazepam.
Take with or without food. Taking bromazepam with food may reduce its Cmax and AUC.

## Chemical Information

**DrugBank ID:** DB01558

**Synonyms:** Bromacepam
Bromazepam
Bromazepamum

**Chemical Formula:** C
14
H
10
BrN
3
O

**SMILES:** BrC1=CC2=C(NC(=O)CN=C2C2=CC=CC=N2)C=C1

**Weight:** Average: 316.153
Monoisotopic: 315.000724604

**IUPAC Name:** 7-bromo-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepin-2-one

## Additional Information

### Modality

Small Molecule

### Patents

0

### Indicated Conditions

2

### Phase 0

0

### Phase 1

0

### Phase 2

0

### Phase 3

2

### Phase 4

0

### Therapeutic Categories

Benzodiazepines and benzodiazepine
derivatives

### Summary

Bromazepam
is a short-acting benzodiazepine with intermediate onset commonly used to treat panic disorders and severe anxiety.

### Generic Name

Bromazepam

### DrugBank Accession Number

DB01558

### Groups

Approved, Illicit

### Structure

3D
Download
MOL
SDF
3D-SDF
PDB
SMILES
InChI
Similar Structures
Structure for Bromazepam (DB01558)
×
Close

### External IDs

RO 5-3350
RO-5-3350

### Associated Conditions

Indication Type
Indication
Combined Product Details
Approval Level
Age Group
Patient Characteristics
Dose Form
Symptomatic treatment of
Acute anxiety
••••••••••••
Create Account
Symptomatic treatment of
Severe anxiety
••••••••••••
Create Account
Create Account

### Mechanism of action

Bromazepam binds to the GABA-A receptor producing a conformational change and potentiating its inhibitory effects. Other neurotransmitters are not influenced.
Target
Actions
Organism
A
GABA(A) Receptor
positive allosteric modulator
Humans
A
GABA(A) Receptor Benzodiazepine Binding Site
ligand
Humans

### Volume of distribution

1.56 L/kg

### Protein binding

70%

### Route of elimination

Urine (69%), as metabolites

### Clearance

0.82 mL/min/kg.

### International/Other Brands

Calmepam
/
Creosedin
/
Durazanil
/
Lectopam
/
Lekotam
/
Lexaurin
/
Lexilium
/
Lexomil
/
Lexotan
/
Normoc
/
Ultramidol

### Brand Name Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Bromazepam
Tablet
3 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Bromazepam
Tablet
1.5 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Bromazepam
Tablet
6 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Bromazepam-1.5 - Tab 1.5mg
Tablet
1.5 mg
Oral
Pro Doc Limitee
1997-05-20
2010-07-13
Canada
Bromazepam-3 - Tab 3mg
Tablet
3 mg
Oral
Pro Doc Limitee
1996-12-04
2019-04-10
Canada

### Generic Prescription Products

Name
Dosage
Strength
Route
Labeller
Marketing Start
Marketing End
Region
Image
Alti-bromazepam 1.5mg Tablets
Tablet
1.5 mg
Oral
Altimed Pharma Inc.
1996-12-31
2005-05-27
Canada
Alti-bromazepam 3mg Tablets
Tablet
3 mg
Oral
Altimed Pharma Inc.
1995-12-31
2005-05-27
Canada
Alti-bromazepam 6mg Tablets
Tablet
6 mg
Oral
Altimed Pharma Inc.
1996-12-31
2005-05-27
Canada
Apo-bromazepam
Tablet
6 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada
Apo-bromazepam
Tablet
1.5 mg
Oral
Apotex Corporation
1995-12-31
Not applicable
Canada

### ATC Codes

N05BA08 — Bromazepam
N05BA — Benzodiazepine derivatives
N05B — ANXIOLYTICS
N05 — PSYCHOLEPTICS
N — NERVOUS SYSTEM

### Drug Categories

Anti-Anxiety Agents
Benzazepines
Benzodiazepine hypnotics and sedatives
Benzodiazepines and benzodiazepine derivatives
Benzodiazepinones
Central Nervous System Agents
Central Nervous System Depressants
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 CYP2C19 Substrates
Cytochrome P-450 CYP2E1 Inhibitors
Cytochrome P-450 CYP2E1 Inhibitors (strength unknown)
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 Substrates
Drugs that are Mainly Renally Excreted
GABA Agents
GABA Modulators
Heterocyclic Compounds, Fused-Ring
Hypnotics and Sedatives
Muscle Relaxants
Muscle Relaxants, Centrally Acting Agents
Nervous System
Neurotransmitter Agents
Psycholeptics
Psychotropic Drugs
Tranquilizing Agents

### Chemical TaxonomyProvided byClassyfire

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Alpha amino acids and derivatives
/
Pyridines and derivatives
/
Benzenoids
/
Aryl bromides
/
Heteroaromatic compounds
/
Secondary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organobromides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 5 more
Substituents
1,4-benzodiazepine
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl bromide
/
Aryl halide
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organobromide
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Pyridine
/
Secondary carboxylic acid amide
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

### Kingdom

Organic compounds

### Super Class

Organoheterocyclic compounds

### Class

Benzodiazepines

### Sub Class

1,4-benzodiazepines

### Direct Parent

1,4-benzodiazepines

### Alternative Parents

Alpha amino acids and derivatives
/
Pyridines and derivatives
/
Benzenoids
/
Aryl bromides
/
Heteroaromatic compounds
/
Secondary carboxylic acid amides
/
Lactams
/
Ketimines
/
Propargyl-type 1,3-dipolar organic compounds
/
Azacyclic compounds
/
Organopnictogen compounds
/
Organobromides
/
Organic oxides
/
Hydrocarbon derivatives
/
Carbonyl compounds
show 5 more

### Substituents

1,4-benzodiazepine
/
Alpha-amino acid or derivatives
/
Aromatic heteropolycyclic compound
/
Aryl bromide
/
Aryl halide
/
Azacycle
/
Benzenoid
/
Carbonyl group
/
Carboxamide group
/
Carboxylic acid derivative
/
Heteroaromatic compound
/
Hydrocarbon derivative
/
Imine
/
Ketimine
/
Lactam
/
Organic 1,3-dipolar compound
/
Organic nitrogen compound
/
Organic oxide
/
Organic oxygen compound
/
Organobromide
/
Organohalogen compound
/
Organonitrogen compound
/
Organooxygen compound
/
Organopnictogen compound
/
Propargyl-type 1,3-dipolar organic compound
/
Pyridine
/
Secondary carboxylic acid amide
show 17 more

### Molecular Framework

Aromatic heteropolycyclic compounds

### Affected organisms

Humans and other mammals

### UNII

X015L14V0O

### CAS number

1812-30-2

### InChI Key

VMIYHDSEFNYJSL-UHFFFAOYSA-N

### InChI

InChI=1S/C14H10BrN3O/c15-9-4-5-11-10(7-9)14(17-8-13(19)18-11)12-3-1-2-6-16-12/h1-7H,8H2,(H,18,19)

### General References

Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [
Article
]
Oda M, Kotegawa T, Tsutsumi K, Ohtani Y, Kuwatani K, Nakano S: The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. Eur J Clin Pharmacol. 2003 Nov;59(8-9):615-9. Epub 2003 Sep 27. [
Article
]
van Harten J: Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet. 1995;29 Suppl 1:1-9. doi: 10.2165/00003088-199500291-00003. [
Article
]
Ochs HR, Greenblatt DJ, Friedman H, Burstein ES, Locniskar A, Harmatz JS, Shader RI: Bromazepam pharmacokinetics: influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther. 1987 May;41(5):562-70. [
Article
]
Lacy CF, Armstrong LL, Goldman MP, Lance LL eds (2007). Lexicomp drug information handbook (15th ed.). Lexicomp.

### External Links

Human Metabolome Database
HMDB0015511
KEGG Drug
D01245
PubChem Compound
2441
PubChem Substance
46505694
ChemSpider
2347
RxNav
1749
ChEBI
31302
ChEMBL
CHEMBL277062
ZINC
ZINC000000001051
Therapeutic Targets Database
DAP001035
PharmGKB
PA10035
Drugs.com
Drugs.com Drug Page
Wikipedia
Bromazepam

### Human Metabolome Database

HMDB0015511

### KEGG Drug

D01245

### PubChem Compound

2441

### PubChem Substance

46505694

### ChemSpider

2347

### RxNav

1749

### ChEBI

31302

### ChEMBL

CHEMBL277062

### ZINC

ZINC000000001051

### Therapeutic Targets Database

DAP001035

### PharmGKB

PA10035

### Drugs.com

Drugs.com Drug Page

### Wikipedia

Bromazepam

### Packagers

United States Pharmacopeial Convention Inc.

### Dosage Forms

Form
Route
Strength
Tablet
Oral
3.000 mg
Tablet
Oral
3 mg/1
Tablet
Oral
6 mg/1
Tablet
Oral
6 mg
Suspension
Oral
6 mg
Solution / drops
Oral
2.5 MG/ML
Tablet
Oral
1.5 MG
Tablet
Oral
3 MG
Tablet, film coated
Oral
Capsule
Oral
Solution / drops
Oral
Capsule
Oral
Capsule
Oral
1.5 MG
Capsule
Oral
12 MG
Capsule
Oral
3 MG
Capsule
Oral
6 MG
Tablet
Oral
300000 mg
Tablet
Oral
Tablet
Oral
3 mg / tab
Tablet
Oral
6.000 mg
Tablet
Oral
6 mg / tab

### Prices

Unit description
Cost
Unit
Lectopam 6 mg Tablet
0.25USD
tablet
Lectopam 3 mg Tablet
0.17USD
tablet
Apo-Bromazepam 6 mg Tablet
0.13USD
tablet
Gen-Bromazepam 6 mg Tablet
0.13USD
tablet
Novo-Bromazepam 6 mg Tablet
0.13USD
tablet
Apo-Bromazepam 3 mg Tablet
0.09USD
tablet
Gen-Bromazepam 3 mg Tablet
0.09USD
tablet
Novo-Bromazepam 3 mg Tablet
0.09USD
tablet
Apo-Bromazepam 1.5 mg Tablet
0.07USD
tablet
Gen-Bromazepam 1.5 mg Tablet
0.07USD
tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

### State

Solid

### Experimental Properties

Property
Value
Source
logP
2.05
SANGSTER (1994)

### Predicted Properties

Property
Value
Source
Water Solubility
0.0399 mg/mL
ALOGPS
logP
2.09
ALOGPS
logP
2.54
Chemaxon
logS
-3.9
ALOGPS
pKa (Strongest Acidic)
12.24
Chemaxon
pKa (Strongest Basic)
2.65
Chemaxon
Physiological Charge
0
Chemaxon
Hydrogen Acceptor Count
3
Chemaxon
Hydrogen Donor Count
1
Chemaxon
Polar Surface Area
54.35 Å
2
Chemaxon
Rotatable Bond Count
1
Chemaxon
Refractivity
76.99 m
3
·mol
-1
Chemaxon
Polarizability
28.11 Å
3
Chemaxon
Number of Rings
3
Chemaxon
Bioavailability
1
Chemaxon
Rule of Five
Yes
Chemaxon
Ghose Filter
Yes
Chemaxon
Veber's Rule
No
Chemaxon
MDDR-like Rule
No
Chemaxon

### Predicted ADMET Features

Property
Value
Probability
Human Intestinal Absorption
+
0.9937
Blood Brain Barrier
+
0.9848
Caco-2 permeable
+
0.7571
P-glycoprotein substrate
Substrate
0.5741
P-glycoprotein inhibitor I
Non-inhibitor
0.7251
P-glycoprotein inhibitor II
Non-inhibitor
0.924
Renal organic cation transporter
Non-inhibitor
0.558
CYP450 2C9 substrate
Non-substrate
0.8385
CYP450 2D6 substrate
Non-substrate
0.9117
CYP450 3A4 substrate
Substrate
0.7117
CYP450 1A2 substrate
Inhibitor
0.9381
CYP450 2C9 inhibitor
Non-inhibitor
0.6329
CYP450 2D6 inhibitor
Non-inhibitor
0.8511
CYP450 2C19 inhibitor
Non-inhibitor
0.5719
CYP450 3A4 inhibitor
Non-inhibitor
0.7405
CYP450 inhibitory promiscuity
High CYP Inhibitory Promiscuity
0.6441
Ames test
Non AMES toxic
0.8607
Carcinogenicity
Non-carcinogens
0.8704
Biodegradation
Not ready biodegradable
1.0
Rat acute toxicity
2.2416 LD50, mol/kg
Not applicable
hERG inhibition (predictor I)
Weak inhibitor
0.9974
hERG inhibition (predictor II)
Non-inhibitor
0.7977
ADMET data is predicted using
admetSAR
, a free tool for evaluating chemical ADMET properties. (
23092397
)

### Spectra

Spectrum
Spectrum Type
Splash Key
Predicted GC-MS Spectrum - GC-MS
Predicted GC-MS
splash10-000i-0091000000-cf3c3fba2d2e801551b1
Mass Spectrum (Electron Ionization)
MS
splash10-00n0-9463000000-abe7fdab778f08fe18c4
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-03di-0049000000-67c4bd48b889caf68ca3
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-000i-0090000000-8d6819f4db99e73f4dbe
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-002r-6090000000-f5e0ef1096bea72d5c89
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9010000000-19864d6c0a50c513bb18
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-59557fda51a0ea2c63d7
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QFT , negative
LC-MS/MS
splash10-004i-9000000000-6b0acd4d149e1fb20f9a
LC-MS/MS Spectrum - LC-ESI-QTOF , positive
LC-MS/MS
splash10-014i-0379000000-14ceeb34a706f6a12f41
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014i-0009000000-09662342e908d558048e
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-014i-0029000000-4b93291583996cb3cbda
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-05o0-0492000000-035f589c482b481c5152
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053r-1890000000-1997ad0374625359f483
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053r-1960000000-4f105348e7e7804313ce
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-053r-1930000000-b0f688a41f88a133b74b
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0f89-1910000000-c0dd1d47a44a292c87b6
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-0fb9-2900000000-706d4c35cde468a8387d
LC-MS/MS Spectrum - LC-ESI-QFT , positive
LC-MS/MS
splash10-004i-6900000000-85795e315602b7e61a6b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0009000000-99f4dfe5439d3dd8c80f
Predicted MS/MS Spectrum - 10V, Negative (Annotated)
Predicted LC-MS/MS
splash10-03di-0009000000-b2c47603b92e2e6a3ba0
Predicted MS/MS Spectrum - 20V, Negative (Annotated)
Predicted LC-MS/MS
splash10-03di-4009000000-5a053eaa9e6f8096bc0c
Predicted MS/MS Spectrum - 20V, Positive (Annotated)
Predicted LC-MS/MS
splash10-014i-0009000000-145bc9aa0c21e6a0e341
Predicted MS/MS Spectrum - 40V, Negative (Annotated)
Predicted LC-MS/MS
splash10-004i-9020000000-448369b122422b784871
Predicted MS/MS Spectrum - 40V, Positive (Annotated)
Predicted LC-MS/MS
splash10-052p-0490000000-ed76996c5885f708c7e0
Predicted 1H NMR Spectrum
1D NMR
Not Applicable
Predicted 13C NMR Spectrum
1D NMR
Not Applicable

### Chromatographic Properties

Collision Cross Sections (CCS)
Adduct
CCS Value (Å
2
)
Source type
Source
[M-H]-
163.6724324
predicted
DarkChem Lite v0.1.0
[M-H]-
157.40865
predicted
DeepCCS 1.0 (2019)
[M+H]+
164.2958324
predicted
DarkChem Lite v0.1.0
[M+H]+
159.80421
predicted
DeepCCS 1.0 (2019)
[M+Na]+
163.8897324
predicted
DarkChem Lite v0.1.0
[M+Na]+
165.81105
predicted
DeepCCS 1.0 (2019)

### Kind

Protein

### Organism

Humans

### Pharmacological action

Unknown

### Actions

Inhibitor

### Curator comments

Information regarding this enzyme action is limited in the literature at this time.

### General Function

A cytochrome P450 monooxygenase involved in the metabolism of fatty acids (PubMed:10553002, PubMed:18577768). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:10553002, PubMed:18577768). Catalyzes the hydroxylation of carbon-hydrogen bonds. Hydroxylates fatty acids specifically at the omega-1 position displaying the highest catalytic activity for saturated fatty acids (PubMed:10553002, PubMed:18577768). May be involved in the oxidative metabolism of xenobiotics (Probable)

### Specific Function

4-nitrophenol 2-monooxygenase activity

### Gene Name

CYP2E1

### Uniprot ID

P05181

### Uniprot Name

Cytochrome P450 2E1

### Molecular Weight

56848.42 Da

